Skip to Main Content

Discover HArmonyCa™

The future is 2-in-1 treatment. 1,2

Searching for a non-surgical lift to give you a refreshed look with lasting results? 

HArmonyCa™ could be for you…

HArmonyCa™ is designed to help rejuvenate skin by addressing multiple signs of facial ageing in one treatment! 1,2−4,*,†,‡,§

It’s a dual-action facial injectable combining two ingredients that work in harmony: HA (hyaluronic acid) and CaHA (Calcium hydroxyapatite). 1,5,*,†,§

Discover the power of an immediate lifting effect that may last up to six months.1,5,6,*, †,‡‡,§

* Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration and safety profile.1

† Ultrasound and elastography examinations were performed. When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment an increase in collagen in the treated areas was confirmed.1

‡ Vectra® H2 (Canfield Scientific, Inc.) was used to assess volumetric changes, with a median (interquartile-range) volume increased by 2.1 (1.9–2.3) cc and 2.1 (1.8–2.2) cc in the right-and left-side, respectively, p<0.0001 each at Day 180.1

§ Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in facial tension vector (FTV) at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile-range) increased by 2.2 (1.6– 2.2) mm and 2.0 (1.7–2.2) mm in the right and left side, respectively p < 0.0001 each, 180 days after treatment.1

‡‡ Results based on a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks, which showed that HArmonyCa™ led to an immediate lifting-effect following injection.6

1. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;00:1–12.
2. Swift A et al. Aesthet Surg J. 2020;sjaa339.
3. Kahn DM, Shaw RB. Facial Plast Surg. 2010;26:350–355.
4. Coleman SR, Grover R. Aesthet Surg J. 2006;26:S4-S9.
5. Allergan Aesthetics. HArmonyCa™ Lidocaine IFU. M032 V01. 2021.
6. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Lift capacity. October 2023. REF-84448.

How does HArmonyCa™ work? 

Restore firmness, elasticity and lost volume1,2−4,*,†,‡

HArmonyCa™ looks to help skin rebuild from within.1, 5,*,†  

This 2-in-1 facial injectable contains: 5

1. HA to immediately restore lost volume1,* and
2. CaHA to support your body’s natural collagen production to help firm, tighten and lift skin1,5,*,†,**

* Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration and safety profile.1

† Ultrasound and elastography examinations were performed. When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment an increase in collagen in the treated areas was confirmed.1

‡ Vectra® H2 (Canfield Scientific, Inc.) was used to assess volumetric changes, with a median (interquartile-range) volume increased by 2.1 (1.9–2.3) cc and 2.1 (1.8–2.2) cc in the right-and left-side, respectively, p<0.0001 each at Day 180.1

** Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in facial tension vector (FTV) at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile-range) increased by 2.2 (1.6– 2.2) mm and 2.0 (1.7–2.2) mm in the right and left side, respectively p < 0.0001 each, 180 days after treatment.1

1. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;00:1–12.
2. Swift A et al. Aesthet Surg J. 2020;sjaa339.
3. Kahn DM, Shaw RB. Facial Plast Surg. 2010;26:350–355.
4. Coleman SR, Grover R. Aesthet Surg J. 2006;26:S4-S9.
5. Allergan Aesthetics. HArmonyCa™ Lidocaine IFU. M032 V01. 2021.

Why HArmonyCa™? 

HACA / A / - / Icons / Circle

The facial ageing is a complex process 

HArmonyCa™  has the potential to rebuild your skin from within1,2,*,†

HACA / A / - / Icons / Circle

One treatment.1 Two effects.1 Minimal downtime. 1,#

HArmonyCa™ combines two components in one injection – HA and CaHA – aiming for two desired effects.1 

Effect one: an immediate lifting result. 3,‡  This is down to HA in restoring lost volume. 2,*

Effect two: firmer, tighter skin with long-lasting results. This is down to CaHA gradually helping your body to produce its own collagen for up to 6 months.1,2,*,†,**

#Individual treatment results may vary. 
HACA / A / - / Icons / Circle

Experience satisfaction

Leave the clinic with potentially instant results – which could get better with time! 1,3,*,†,**,‡

Why not join the 92% of people seeing improvements in their skin with HArmonyCa™? 4,¶,***

* Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration and safety profile.2

† Ultrasound and elastography examinations were performed. When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment an increase in collagen in the treated areas was confirmed.2

#Individual treatment results may vary.1

‡ Results based on a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks, which showed that HArmonyCa™ led to an immediate lifting-effect following injection.3

** Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in facial tension vector (FTV) at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile-range) increased by 2.2 (1.6– 2.2) mm and 2.0 (1.7–2.2) mm in the right and left side, respectively p < 0.0001 each, 180 days after treatment.2

¶ A post marketing clinical follow up of safety and performance of HArmonyCa™ (N=162). Significant improvements were reported in treated facial regions.4

*** A post-marketing clinical analysis of HArmonyCa™ in which a subset of patients (N=48) evaluated effectiveness of treatment using the Global Aesthetic Improvement Scale (GAIS).4

1. Allergan Aesthetics. HArmonyCa™ Lidocaine IFU. M032 V01. 2021.  
2. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;00:1–12.
3. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Lift capacity. October 2023. REF-84448.
4. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Clinical Study Report. October 2023. REF-99624.

 

UK-HAR-230132 | Date of prep: September 2024

Adverse events should be reported.

Reporting of Side effects:

UK patients: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can help by reporting side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at ProductSurveillance_EAME@allergan.com. By reporting side effects, you can help provide more information on the safety of this product.

 

Irish patients: If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via www.hpra.ie.

 

  1. Allergan Aesthetics. HArmonyCa™ Lidocaine IFU. M032 V01. 2021. 

The information on this website is intended for informational and educational purposes only and should not be used as a substitute for advice provided by a qualified medical aesthetics practitioner.

HArmonyCa™  Lidocaine is a dermal filler intended for facial soft tissue augmentation and should be injected into the deep dermal and sub-dermal layers1. The lidocaine in the product is for reducing pain during treatment1. HArmonyCa™ Lidocaine is referred to as HArmonyCa™. Treatment with HArmonyCa™ is intended for adults 18 years and over only.

Materials provided by Allergan Aesthetics, an AbbVie company. HArmonyCa™ and its design are registered trademarks of Allergan Aesthetics or its affiliates, used under license by AbbVie Ltd. ©2024 Abbvie. All Rights Reserved